Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 01, 2014, 03:54:41 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 640696
  • Total Topics: 48667
  • Online Today: 226
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 6
Guests: 206
Total: 212

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Small Interfering RNA (siRNA) & Aptamer Dual Approach  (Read 1497 times)

0 Members and 1 Guest are viewing this topic.

Offline Cosmicdancer

  • Member
  • Posts: 150
Small Interfering RNA (siRNA) & Aptamer Dual Approach
« on: February 03, 2011, 02:35:45 PM »
http://www.cityofhope.org/about/publications/hope-news/2011-vol-06-num-3-january-24/Pages/dual-approach-may-offer-way-to-conquer-hiv.aspx

Dual approach may offer way to conquer HIV    
By Darrin S. Joy

A new method of targeting the virus that causes AIDS may provide a powerful one-two punch against the disease, according to a Jan. 19 report in the journal Science Translational Medicine. The findings could improve HIV-positive patients’ chances of overcoming the infection.
 
Scientists led by John J. Rossi, Ph.D., chair of the Department of Molecular and Cellular Biology and Lidow Family Research Chair, developed a small piece of genetic material — called an RNA aptamer — that both interferes with HIV’s ability to infect cells and acts as a delivery vehicle for another anti-HIV molecule.

HIV gets its start in the body by infecting white blood cells called T cells and hijacking cells’ internal machinery. The virus then forces cells to make more HIV copies until the cells finally burst, releasing virus particles into the bloodstream where they find other T cells to infect and begin the destructive process all over again.

Current antiviral therapies can slow the progression of HIV infection and stave off disease, but the drugs can have toxic side effects. Also, HIV can develop resistance to the drugs.

Rossi and his team have been working on alternative ways of disrupting the HIV life cycle and stopping the virus in its tracks.

In previous research, they designed molecules called small interfering RNAs, or siRNAs, that target and shut down genes that HIV needs to multiply. The method has shown some success; however, getting siRNAs into T cells where they can do their job is difficult.

Enter the RNA aptamer.

Rossi’s team developed the aptamer to recognize and attach itself to a key protein that sticks up from the outer surface of HIV.

They found that this RNA aptamer interferes with HIV’s ability to reproduce, but they took it one step further and attached an siRNA to it. Now, the RNA aptamer pulls double duty: It not only interferes with HIV growth, but also acts as a carrier to deliver the anti-HIV siRNA molecule to infected cells.

Testing the combination in laboratory mice, the researchers found promising results.

“Adding the siRNA to the aptamer gave a much longer antiviral effect, lasting several weeks beyond the last dose,” Rossi said.

Further, the new therapy showed no toxic effects.

“The combined aptamer-siRNA agent provides an attractive, nontoxic therapeutic approach for treatment of HIV infection,” Rossi said.

The team now plans to conduct preclinical tests of the new therapy aimed at clearing the way to future human clinical trials, he said, “perhaps in patients who have developed drug-resistant virus.”

City of Hope coauthors on the study included Jiehua Zhou, Ph.D, Haitang Li, Ph.D., David D. Smith, Ph.D., and Piotr Swiderski, Ph.D.
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
June, 2008 - undetectable, 612 cd4
January, 2009 - undetectable, 670 cd4
May, 2009 - undetectable, 593 cd4
Sept, 2009 - 83 vl, 763 cd4, 34%
Dec, 2009 - undetectable, 889 cd4, 32%
April, 2010 - undetectable, 860 cd4, 31%
October, 2010 - undetectable, 800 cd4, 38%
April, 2011 - undetectable, t-cell test not done
October, 2011 - undetectable
April, 2012 - undetectable, 850 cd4, 39%
November, 2012 - undetectable, 901 cd4, 41%
April, 2013 - undetectable, 846 cd4, 36%
October, 2013 - undetectable
May, 2014 - undetectable, 784 cd4, 48%

Offline Hellraiser

  • Member
  • Posts: 4,136
  • Semi-misanthropic
Re: Small Interfering RNA (siRNA) & Aptamer Dual Approach
« Reply #1 on: February 03, 2011, 02:46:25 PM »
This sounds fantastic, lets hope it works.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.